<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Keytruda on FinanClub</title>
    <link>https://finan.club/tags/keytruda/</link>
    <description>Recent content in Keytruda on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 02 Feb 2024 09:07:39 +0000</lastBuildDate><atom:link href="https://finan.club/tags/keytruda/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Fri, 02 Feb 2024 09:07:39 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:-54
Chances: Merck &amp;amp; Co Inc has reported better-than-expected fourth-quarter results, with revenue significantly boosted year-over-year by demand for its cancer drug Keytruda. The company remains a darling of Wall Street analysts, and shares are up 20.1% over the past 12 months, indicating strong investor confidence.</description>
    </item>
    
  </channel>
</rss>
